A prospective observational study on the comparison of ctDNA and traditional indicators for early prediction of neoadjuvant therapy efficacy in patients with colorectal cancer liver metastases

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100043990

Enrollment

Unknown

Registered

2021-03-06

Start date

2021-04-01

Completion date

Unknown

Last updated

2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer liver metastasis

Interventions

Included patients:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) No history of allergy to chemotherapy drugs or components; 2) Age between 18 and 75 years old; 3) No history of serious arrhythmia or heart failure, etc.; 4) No history of severe ventilatory dysfunction or severe lung infection; 5) No acute or chronic renal failure, creatinine clearance rate > 40 mL/min; 6) Liver function Child A: total bilirubin = 28 g/L, AST, ALT, ALP = 1.5 x 10^9/L, Hb >= 8.5g/L, PLT >= 75 x 10^9/L. 8) Coagulation function: INR >= 2.3; 9) ECOG score = 3 points; 13) Can understand and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Women during pregnancy or breastfeeding; 2) Patients with other malignant tumors; 3) Patients with mental illness; 4) Patients who have participated in other clinical trials within 3 months; 5) Patients who have received chemotherapy within 6 months.

Design outcomes

Primary

Measure	Time frame
ctDNA;Tumor imaging regression (RECIST 1.1);tumor regression grade;	—

Secondary

Measure	Time frame
disease free survival;overall survival;	—

Countries

China

Contacts

Public ContactChen Jinhong

Huashan Hospital, Fudan University

jhchen@hotmail.com+86 13801977742

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026